<DOC>
	<DOCNO>NCT00561587</DOCNO>
	<brief_summary>Due Quetiapine 's particular promise receptor profile , want examine efficacy concern relapse prevention alcoholic suffer persist crave and/or affective symptom ( persist sleep disorder , persist excitement , persist depressive symptom , persist anxiety symptom ) comparison match placebo double-blind pilot study . We want compare course mention crave affective symptom medication quetiapine / match placebo .</brief_summary>
	<brief_title>Quetiapine v . Placebo Alcohol Relapse Prevention - Pilot Study</brief_title>
	<detailed_description>Naltrexone Acamprosate best evaluate establish therapy option relapse prevention alcoholic present ( Litten et al . 1996 , Mann et al . 2004 ) . Studies cue exposure show Naltrexone ( Monti et al . 1999 ) Haloperidol ( Modell et al . 1993 ) block stimulus trigger crave . In addition , indicate may also stop crave alcohol consumption induce prim dose alcohol ( Modell et al . 1993 ) . However , clinical relevance Haloperidol rather limit due risk extrapyramidal side effect . New atypical dopamine antagonist report profile well , without risk develop extrapyramidal side effect . In placebo-controlled clinical trial , atypical antipsychotic Olanzapine prove reduce crave alcohol alcohol exposure prim dose alcohol non-dependent heavy social drinker ( Hutchison et al . 2001 ) . However , Amisulpride dose 50 mg per day fail prevent alcohol relapse double-blind , placebo-controlled study 71 patient 6 month ( Marra et al . 2002 ) .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Alcohol dependence accord ICD10 DSMIV since minimum 12 month . Detoxified male female age 18 65 year . Abstinence minimum 7 day maximum 21 day randomization . Craving : minimum 5 point randomisation ( OCDSG ) Free inform consent give write form . Women childbearing potential must use medically accept method contraception . Only method Pearlindex low 1 % regard acceptable hormonal contraception , surgical sterilization , bilateral ovarectomy , postmenopause ( WHO definition : natural menopause retrospectively least one year amenorrhoe ) without hormonal replacement therapy within past 5 month . Patients suffer psychotic disease and/or depression psychotic symptom and/or demented patient , patient longlasting continous treatment psychotropic drug . Known substance abuse alcohol nicotine ( except dependence full remission ) define DSMIV criterion . Patients positive urine toxicology screen exclude satisfy DSMIV criterion abuse dependence . Hepatitis ( GGT AST three time normal range ) . An absolute neutrophil count ( ANC ) ≤ 1.5 x 109 per liter . A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : unstable DM define enrollment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % ; patient admit hospital treatment DM DM relate illness past 12 week ; patient physicians care DM ; physicians responsible patient´s DM care indicate patient´s DM control ; physician responsible patient´s DM care approve patient´s participation study ; patient dose oral hypoglycemic drug ( ) and/or diet 4 week prior randomization . [ For thiazolidinediones ( glitazones ) period le 8 week ] ; patient take insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week . Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study . Evidence clinical relevant disease clinical finding unstable , opinion investigator , would negatively affect study medication would affect study medication . Patients , investigator 's judgment , pose current serious suicidal risk make suicide attempt within past 6 month . Restricted complete legal incapacity . Additional psychotherapy 1 month prior randomisation participation study . History idiopathic orthostatic hypotension , condition would predispose hypotension ( e.g . dehydration , hypovolemia ) . Risk transmit human immunodeficiency virus ( HIV ) hepatitis B , C , via blood body fluid ( judged investigator ) . Positive HIVserology screen visit . Known regular treatment Quetiapine prior randomisation . Hypersensitivity Quetiapine constituent investigational product . Simultaneous intake CytochromeP4503A4 inducer inhibitor : Use drug induce inhibit hepatic metabolizing cytochrome 3A4 enzyme within 2 week prior randomization study period , e.g . inducer : carbamazepine , phenytoin , barbiturate , rifampicin , rifabutin , glucocorticoid , thioridazine St. Johns wort , e.g . inhibitor : HIVproteaseinhibitors , antimycotic azole type ( e.g . ketoconazole ( except topical use ) , itroconazole , fluconazole ) , erythromycin , clarithromycin , fluvoxamine , nefazodone , troleandomycin , indinavir , nelfinavir , ritonavir , saquinavir Female patient pregnant lactate . Women childbearing potential use medically accept method contraception Pearlindex &gt; 1 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>novel antipsychotic</keyword>
	<keyword>quetiapine</keyword>
	<keyword>depression</keyword>
	<keyword>psychopathology</keyword>
</DOC>